(19)
(11) EP 1 597 250 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.05.2010 Bulletin 2010/20

(45) Mention of the grant of the patent:
07.04.2010 Bulletin 2010/14

(21) Application number: 04710393.2

(22) Date of filing: 12.02.2004
(51) International Patent Classification (IPC): 
C07D 401/14(2006.01)
A61K 31/44(2006.01)
 C07D 403/14(2006.01)
A61K 31/40(2006.01)
(86) International application number:
PCT/EP2004/001323
(87) International publication number:
WO 2004/072062 (26.08.2004 Gazette 2004/35)

(54)

INDOLYLMALEIMIDE DERIVATIVES

INDOLYLMALEIMID DERIVATE

DERIVES D'INDOLYLMALEIMIDE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 13.02.2003 GB 0303319

(43) Date of publication of application:
23.11.2005 Bulletin 2005/47

(60) Divisional application:
09004073.4 / 2075249

(73) Proprietors:
  • Novartis AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • VON MATT, Peter
    CH-4105 Biel-Benken (CH)
  • WAGNER, Jürgen
    CH-4103 Bottmingen (CH)

(74) Representative: Patent- und Rechtsanwaltssozietät Maucher, Börjes & Kollegen et al
Urachstrasse 23
79102 Freiburg i. Br.
79102 Freiburg i. Br. (DE)


(56) References cited: : 
WO-A-02/38561
US-A- 5 057 614
 WO-A-03/076398
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).